Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 22, 2025BMC CancerOpen Access

ASAH1-mediated sphingolipid metabolic reprogramming in venetoclax resistance of AML: beyond the monocytic phenotypes

View Full Paper
Ask AI
Bookmark
Share

Authors

LZLei ZhaoXXXinrong XiangAZAiling Zhong

Discussion

Loading...

Member takes

Overview

Analysis shows that targeting sphingolipid metabolism improves venetoclax sensitivity in AML, indicating therapeutic potential.

Key Points

  • The aim is to understand how sphingolipid metabolism contributes to venetoclax resistance in acute myeloid leukemia.
  • Integrated bulk and single-cell RNA sequencing analyses of AML samples.
  • Conducted lipidomic sequencing of venetoclax-resistant cell lines.
  • Evaluated the effect of knocking down ASAH1 on venetoclax sensitivity.
  • Monocytic AML cells showed elevated sphingolipid metabolism genes linked to poor venetoclax response.
  • ASAH1 was upregulated in resistant models, while SPHK1 was downregulated.
  • Knocking down ASAH1 increased venetoclax sensitivity without impacting monocytic markers.

Cite This Study

Zhao et al. (2025) studied this question.

synapsesocial.com/papers/6924e3e6c0ce034ddc34ea33https://doi.org/10.1186/s12885-025-15272-9
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Single-cell transcriptomic insights into venetoclax response and resistance in secondary AML evolving from MDS2025
  2. 2Phenotypic heterogeneity and remodeling drive resistance to venetoclax treatment in acute myeloid leukemia2025 · 1 citations
  3. 3Dietary serine restriction increases venetoclax efficacy in Acute Myeloid Leukemia2025
  4. 4Drivers of clinical resistance to venetoclax and hypomethylating agents in acute myeloid leukemia and strategies for improving efficacy2026 · 2 citations
  5. 5Abstract 5852: Tumor gene expression patterns affecting response to BCl-2 inhibitor venetoclax in acute myeloid leukemia2024